Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal GrowthStatus: open
PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth
Treatment for Breast Cancer
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.
SponsorsThis trial is sponsored by Alliance Foundation Trials, LLC.
Interested in Clinical Trial?
Providers Associated With This Trial
- Daniel G. Cameron, M.D.Medical OncologistSenior Staff Medical Oncologist, Medical Oncology Service; Associate Professor of Interdisciplinary Clinical Oncology